Janus Henderson Group PLC Immatics N.V. Transaction History

Janus Henderson Group PLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$9.78 - $13.49 $4.94 Million - $6.81 Million	-504,670 Reduced 79.11%	133,284 $1.55 Million
Q1 2024 May 15, 2024	SELL	$10.23 - $12.94 $679,650 - $859,694	-66,437 Reduced 9.43%	637,954 $6.7 Million
Q4 2023 Feb 14, 2024	BUY	$7.36 - $10.89 $5.18 Million - $7.67 Million	704,391 New	704,391 $7.42 Million

101

75.8M

238K

727K

Ticker IMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,227,000
Market Cap $522M
Description
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

Stay updated on Janus Henderson Group PLC with notifications on news.